Astrazeneca Plc (AZN) Return on Investment ROI from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Astrazeneca Plc  (NASDAQ: AZN)


Astrazeneca Plc's ROI from its fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Astrazeneca Plc's ROI in the fourth quarter of 2025?
Astrazeneca Plc achieved a return on average invested assets (ROI) of 21.6 % in its fourth quarter of 2025, this is above AZN's average return on investment of 11.83%.
Astrazeneca Plcs investments during the 12 months ending in the fourth quarter of 2025 are valued at $58 billion

ROI has improved compared to 17.38% in the third quarter of 2025, due to net income growth.

Within the Healthcare sector 85 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2025 from 0 to 391.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Investment Change TTM 43 % 34.55 % 30.84 % 8.38 % 4.37 %
Y / Y Net Income Change TTM 41.39 % 20.28 % 20.28 % 50.46 % 50.46 %
Investment (TTM) in Millions 61,609 45,219 82,807 45,219 45,097
Return On Investment (TTM) 21.6 % 17.38 % 18.02 % 20.87 % 21.84 %
AZN's Overall Ranking # 391 # 0 # # #
Seq. Investment Change TTM 7.56 % 3.63 % 22.57 % 4.66 % 1.21 %
Seq. Net Income Change TTM 33.64 % 0 % 5.8 % 0 % 13.69 %
Net Income (TTM) in Millions 12,681 9,489 9,489 8,969 8,969

AZN Company Profile >> Back to AZN Roi Comparisons >> See Annual AZN Return On Investment



Return On Investment AZN's Ranking
Within: No.
Industry # 39
Sector # 86
Overall # 391

Return On Investment Statistics
High Average Low
24.72 %
11.83 %
0.35 %
(Dec 31 2020)   (Dec 31 2021)







Financial Statements
Astrazeneca Plc's IV. Quarter Investments $ 61,609 Millions AZN's Balance sheet
Astrazeneca Plc's IV. Quarter Income $ 10,233 Millions Quarterly AZN's Income Statement
AZN's Income by Division See AZN's Income by Division


AZN Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 53,137 45,097 43,137 40,898 46,449
Y / Y Investment Growth 17.83 % 4.54 % 5.47 % -11.95 % 142.68 %
Net Income in Millions 10,233 7,041 5,961 3,293 115
Y / Y Net Income Growth 45.33 % 18.12 % 81.02 % 2763.48 % -96.34 %
Annual Return On Investment 19.26 % 15.61 % 13.82 % 8.05 % 0.25 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 19.26 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
AZN's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for AZN's Competitors
Subscribers only: Roi for Astrazeneca Plc's Suppliers
Subscribers only: Return On Investment for AZN's Customers

Other Ratios
AZN's Roa AZN's Inventory Turnover Ratio AZN's Growth Rates AZN's Dividend Statistics
AZN's Profitability Ratios AZN's Asset Turnover Ratio AZN's Dividend Growth
AZN's Roe AZN's Valuation Ratios AZN's Financial Strength Ratios AZN's Dividend Payout Ratio



Companies with similar Return On Investment at Dec 31 2025, within Healthcare Sector ROI
Aurinia Pharmaceuticals Inc   56.37 %
Pulmatrix Inc   53.09 %
Novavax inc   51.88 %
Q32 Bio Inc   50.33 %
Idexx Laboratories Inc  48.69 %
Theravance Biopharma inc   46.03 %
Elite Pharmaceuticals Inc   45.80 %
Enlivex Therapeutics Ltd  45.75 %
Gsk Plc  44.94 %
Galmed Pharmaceuticals Ltd   43.72 %
Abeona Therapeutics Inc   42.25 %
Alpha Tau Medical Ltd  42.04 %
Dariohealth Corp   41.31 %
Acadia Pharmaceuticals Inc   39.64 %
Medinotec Inc   37.45 %
Zevra Therapeutics Inc   36.78 %
Oramed Pharmaceuticals Inc  35.86 %
Ptc Therapeutics inc   35.12 %
Mettler toledo International Inc   34.74 %
Newgenivf Group Limited  32.05 %
Eli Lilly And Company  31.62 %
Indivior Pharmaceuticals Inc   31.00 %
Hutchmed china Limited  30.87 %
Medpace Holdings Inc   30.44 %
Adma Biologics Inc   28.75 %
Carlisle Companies Incorporated  27.24 %
Incyte Corporation  27.08 %
Vaxart Inc   26.63 %
Compugen Ltd  26.32 %
Arrowhead Pharmaceuticals Inc   25.56 %

Date modified: 2026-07-07T09:23:46+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.